Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT05700058

Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults

Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults — Recruiting • Non-phase study • Diabetes / Metabolic • NCT05700058.

📅 01 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05700058
Start
2023-01-31
Completion
2026-09
ClinicaliQ Trial Snapshot
  • Assessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults — Recruiting • Non-phase study • Diabetes / Metabolic • NCT05700058.
  • One-sentence summary:.
  • This study tests three doses of leucine-enriched whey protein to find which best stimulates muscle building in older people.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Skeletal muscle accounts for approximately 45-55% of total body mass in healthy adults and plays a pivotal role in whole-body metabolic health, locomotion and physical independence. Undesirable loss of skeletal muscle mass (atrophy) is, however, a common feature of many diseases and scenarios including ageing, bed rest/immobilisation, cancer and physical inactivity. Despite the exact mechanisms causing muscle atrophy being not yet fully understood, "anabolic resistance" (reduced muscle building in response to protein feeding and exercise) is thought to be key, especially for age-related skeletal muscle losses (known as sarcopenia). As…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Rise in women in their 20s developing Type 2 diabetes
Diabetes / Metabolic · BBC Health · 22 Jul 2026
Young women in their 20s in England are developing type 2 diabetes at increasing rates, representing a shift in disease epidemiology traditionally…
View brief →
Clinical Brief
New drug to stop ‘Ozempic butt’ muscle loss side effect of obesity jabs
Diabetes / Metabolic · BBC Health · 08 Jun 2026
Weight loss from GLP-1 receptor agonists results in approximately 33% muscle loss alongside fat loss, necessitating clinical attention to body composition changes…
View brief →
Clinical Brief
Why weight-loss jabs work better for some people than others
Diabetes / Metabolic · BBC Health · 10 Apr 2026
Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Clinical Brief
More young women in their 20s are getting type 2 diabetes
Diabetes / Metabolic · BBC Health · 22 Jul 2026
Type 2 diabetes incidence is rising significantly in women aged in their 20s in England, requiring heightened clinical vigilance for early detection…
View brief →
Guideline
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
Diabetes / Metabolic · 09 Jul 2026
Teplizumab is recommended for people aged 8 years and over with stage 2 type 1 diabetes to delay progression to stage 3;…
View guideline →